Latest Breaking News On - China limited nasdaq - Page 3 : comparemela.com

2023-09-29 | NDAQ:HCM | Press Release | HUTCHMED China ADR

(2023-09-29 | NDAQ:HCM) HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Ministry of healthAl qahirahHong kongUnited statesPanmure gordonTakeda closecurlyquoteZhou yiBen atwell alex shawMichael shiNat revgastroenterolhepatolAhcene djaballahChina limited nasdaqDrug administrationEuropean medicines agencyEuropean society for medical oncologyExchange commission

Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet - Takeda Pharmaceutical (NYSE:TAK)

− Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) − Data support regulatory submissions in the U.S.,

Hong kongUnited statesAl qahirahEli lillyGastroenterol hepatolAhcene djaballahStock exchange of hong kongChina limited nasdaqEuropean society for medical oncology congressChina national reimbursement drug listDrug administrationJapan pharmaceuticalsTakeda pharmaceutical company limitedExchange commissionDevices agencyEuropean medicines agency

Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO2 Results in The Lancet

Takeda TSE4502NYSETAK and HUTCHMED China Limited NasdaqAIMHCM HKEX13 HUTCHMED today announced that results of the Phase 3 FRESCO2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer CRC were published in The Lancet.

United statesHong kongAl qahirahEli lillyBen atwell alex shawAnnie chengGastroenterol hepatolMark leeAhcene djaballahJemma nashJun saitoSara noonanZhou yiEuropean society for medical oncology congressJapan pharmaceuticalsSolebury strategic communications

Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet

OSAKA, Japan & CAMBRIDGE, Mass. & HONG KONG & SHANGHAI & FLORHAM PARK, N.J. (BUSINESS WIRE) Jun 15, 2023

Al qahirahUnited statesHong kongBen atwell alex shawJemma nashGastroenterol hepatolSara noonanMark leeZhou yiJun saitoAnnie chengEli lillyAhcene djaballahDrug administrationJapan pharmaceuticalsTakeda pharmaceutical company limited

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongAl qahirahUnited kingdomUnited statesAnnie chengMark leeBen atwell alex shawJemma nashMichael shiAwny farajallahGastroenterol hepatolSara noonanAhcene djaballahJun saitoZhou yiInternational agency for research on cancer